Objective disease responses
| Patient (dose level, mg/kg) . | Age . | Sex . | Diagnosis . | Prior DLI . | Response to ipilimumab . | GVHD after ipilimumab . | Other toxicity . |
|---|---|---|---|---|---|---|---|
| 0414 (1.0) | 64 | M | NHL (mantle cell) | Yes (×2) | PR | No | Transient neutropenia |
| 2517 (3.0) | 21 | M | HD | Yes | CR | No | No |
| 3520 (3.0) | 40 | M | HD | No | CR* | No | Grade 4 pneumonitis* |
| Patient (dose level, mg/kg) . | Age . | Sex . | Diagnosis . | Prior DLI . | Response to ipilimumab . | GVHD after ipilimumab . | Other toxicity . |
|---|---|---|---|---|---|---|---|
| 0414 (1.0) | 64 | M | NHL (mantle cell) | Yes (×2) | PR | No | Transient neutropenia |
| 2517 (3.0) | 21 | M | HD | Yes | CR | No | No |
| 3520 (3.0) | 40 | M | HD | No | CR* | No | Grade 4 pneumonitis* |
Negative effect observed after retreatment with ipilimumab.